Medtronic plc

Equities

MDT

IE00BTN1Y115

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 21:00:02 20/05/2024 BST			5-day change	1st Jan Change
84.51 ^USD	-1.64%		+1.19%	+2.59%

05-17	Medtronic Trial for AFib System Achieves Endpoints	DJ
05-17	Medtronic Says Small-Diameter Defibrillation Lead Meets Safety, Efficacy Goals in Pivotal Trial	MT

Medtronic : PulseSelect™ pulsed field ablation system receives approval in Japan, broadening global impact of paradigm-shifting AFib treatment

May 10, 2024 at 01:26 pm

Rapidly increasing adoption driven by new standard of safety, efficacy and efficiency with excellent physician feedback worldwide Only PFA system indicated for both paroxysmal and persistent AFib System designed to adapt to physician and any electrophysiology (EP) lab workflow May 10, 2024 - Medtronic today announced regulatory approval of its PulseSelect™ pulsed field ablation (PFA) system in [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

Original Link
Permalink

Disclaimer

Medtronic plc published this content on 10 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2024 12:25:04 UTC.

Latest news about Medtronic plc

Medtronic Trial for AFib System Achieves Endpoints	05-17	DJ
Medtronic Says Small-Diameter Defibrillation Lead Meets Safety, Efficacy Goals in Pivotal Trial	05-17	MT
Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints	05-17	CI
Departing Boeing CEO's board status faces Friday vote by shareholders	05-17	RE
Insulet Shares Rise Despite Blue Orca's Short Position	05-14	MT
Arecor Therapeutics collaborates with Medtronic on novel insulin	05-09	AN
Arecor Therapeutics, Medtronic Team Up for Thermostable Insulin Development	05-09	MT
Arecor and Medtronic Diabetes Collaboration	05-09	CI
Medtronic Receives FDA Approval for Inceptiv Spinal Cord Stimulator to Treat Chronic Pain	04-26	MT
Medtronic Gets FDA OK for Inceptiv Closed-Loop Spinal Cord Stimulator	04-26	DJ
Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator	04-26	CI
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength	04-25	RE
Edwards Lifesciences Corporation: The story continues	04-23
Baird Adjusts Medtronic Price Target to $88 From $91	04-17	MT
Integer Holdings to Benefit from Pulsed Field Ablation Market Growth, BofA Says	04-15	MT
Penumbra, Inc. : The underdog in healthcare	04-12
Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO	04-10	CI
Medtronic plc Announces Collaboration with Modernizing Medicine	04-10	CI
ModMed & Medtronic Collaborate to Drive Efficiencies in Documenting Colonoscopies Using AI	04-10	CI
Conflicting signals on rate cuts	04-09
ANALYST RECOMMENDATIONS : Amex, Cisco, Nasdaq, Wells Fargo, Marathon Petroleum...	04-09
Transcript : Medtronic plc - Shareholder/Analyst Call	04-07
Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut? Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women	04-07	CI
Titan Medical Reports Fiscal Year 2023 Results	04-01	MT
Medtronic Says FDA Approved Transcatheter Aortic Valve Replacement System for Heart Valve Disease	03-27	MT

Chart Medtronic plc

Duration

Period

More charts

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

23/05/2024 - Q4 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Medtronic plc : Still struggling to convince

November 24, 2023 at 01:21 pm

More Strategies

Ratings for Medtronic plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

85.92 USD

Average target price

94.77 USD

Spread / Average Target

+10.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
MEDTRONIC PLC	+2.59%	114B
ABBOTT LABORATORIES	-6.23%	181B
BECTON, DICKINSON AND COMPANY	-2.75%	68.29B
DEXCOM, INC.	+5.32%	52.24B
CENCORA, INC.	+7.61%	44.3B
HOYA CORPORATION	+6.67%	42.73B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.17%	32.52B
TERUMO CORPORATION	+20.03%	26.02B
WEST PHARMACEUTICAL SERVICES, INC.	-2.66%	25.91B
ZIMMER BIOMET HOLDINGS, INC.	-2.18%	24.72B

Other Medical Equipment, Supplies & Distribution